Published on 28/11/2025

Use of Surrogates: Temperature, Conductivity, and pH

The pharmaceutical industry is heavily regulated, and ensuring compliant practices surrounding hold times is crucial for maintaining product integrity. The validity of holds on biological materials, especially under conditions of temperature, conductivity, and pH, is critical to ensure that the final product meets required standards. This guide provides a thorough examination of the utilization of surrogates in the context of equipment, bulk, and intermediate hold times. It aims to aid pharmaceutical professionals in designing effective studies that align with regulatory expectations including 21 CFR Part 211, EMA, and other regional practices.

Understanding Hold Times in Pharmaceutical Processes

Hold times are intervals during which biological or pharmaceutical materials are stored before further processing, often involving transport between different stages of production. These hold times can be categorized into:

• Bulk Hold Time: The period during which bulk outputs are stored before processing into final dosage forms.
• Intermediate Hold Time: The duration that intermediate materials are held before final processing or testing.
• Cleaning Hold Time: The time equipment is held in a clean state before being used again.

Understanding and documenting these hold times are pivotal for adhering to microbial limits and ensuring that products remain within acceptable limits for endotoxins and other contaminants. Often, studies are required to establish permissible hold durations based on empirical data and validated methodologies.

The Role of Surrogates in Hold Time Studies

In hold time studies, surrogates are utilized to help assess the stability and safety of biological samples. Surrogates can include indicators for pH, conductivity, and temperature to ensure that the conditions of hold times are optimal for maintaining the quality of the products. The use of these surrogates can provide insights into the physical and chemical changes that could jeopardize product integrity. Below are the common types of surrogates and their application in hold time assessments:

Temperature as a Surrogate

Temperature control is paramount during hold times to prevent the growth of unwanted microbial contaminants. Using temperature monitoring systems, manufacturers can track the temperature throughout the hold time in real time. Understanding the specific temperature thresholds required for stability is crucial, especially for biopharmaceuticals that can be particularly sensitive. Data should reflect:

• Product-specific temperature tolerance levels.
• Statistical analysis of temperature deviations from the desired range.

To ensure compliance with regulations, continued monitoring can be integrated into a robust sampling plan that evaluates the stability of products over an extended duration. Furthermore, regulatory compliance with guidelines outlined in Annex 15 emphasizes the importance of systematic evaluation of hold times, which can leverage temperature data trends.

Conductivity as a Surrogate

Conductivity can be a reliable surrogate for determining the ionic content of a solution, which correlates directly with the potential for microbial growth. Regular monitoring of conductivity levels allows the identification of deviations across hold times. Implementing this monitoring technique has practical implications in assessing the validity of both cleaning processes and bulk hold times.

• Establish conductivity benchmarks aside from the expected product range.
• Develop acceptance criteria that incorporate conductivity variations.

Conductivity readings should be documented as part of the ongoing validation of bioburden trending and incorporation into quality management systems. Regulatory bodies recommend maintaining a careful balance between the acceptability of the conductivity metrics while adhering to microbial limits.

pH Measurement as a Microbial Indicator

The pH level of a solution can greatly impact the stability and pathogen viability within the product. Maintaining a controlled pH range is critical to managing the risk of contamination. As a surrogate, pH is similarly monitored to ensure that the conditions remain within acceptable limits during hold times. Important aspects to include in your pH studies are:

• Identifying the acceptable pH range specific to each batch or formulation.
• Correlating pH levels with microbial growth rates, especially in the context of biological materials.

It’s essential to ensure that measurement probes utilized for pH evaluation are regularly calibrated and maintained as per manufacturers’ instructions to guarantee their reliability.

Designing an Effective Hold Time Study Plan

The development of a comprehensive sampling plan for generating data on hold time studies requires careful consideration. The following steps should guide pharmaceutical professionals in structuring their hold time study plans effectively:

Step 1: Define Parameters and Criteria

Set the necessary benchmarks by establishing relevant parameters such as temperature, pH, and conductivity. The acceptance criteria for each surrogate should be defined early in the study formulation to ensure compliance with microbial limits and endotoxin limits. This will facilitate clear expectations throughout the testing process.

Step 2: Selection of Representative Samples

The sampling strategy involves choosing representative samples from each production batch. It is essential to consider:

• The physical and chemical attributes of the samples to ensure they mimic the expected profile of the products.
• Geographical considerations to maintain consistency and control over the environmental factors affecting stability.

Well-planned representative sampling can enhance the credibility of the collected data and its subsequent analysis.

Step 3: Establishing Test Intervals

Determine the time intervals at which samples will be taken for testing. These intervals should be strategically designed to encompass the entire projected hold time, allowing for a comprehensive assessment of product stability. Establishing these intervals is essential for generating data that assist in validating the proposed hold times and determining whether their duration might be extended further.

Step 4: Data Analysis and Interpretation

Once the testing phase is completed, data analysis is required to determine whether the results align with the established acceptance criteria. This involves the use of statistical techniques to analyze trends and draw insights about the effects of hold time on product integrity. Additionally, correlation between surrogate metrics and microbial growth should be established, which can allow for a data-driven justification for hold time extensions where necessary.

Step 5: Documenting and Reporting Findings

The conclusions drawn from the hold time study should be documented comprehensively, including any deviations from the acceptance criteria, corrective actions taken, and recommendations for future practices. Findings should be compiled in an inspection-ready format to comply with regulatory expectations and to outline proper processes going forward.

Regulatory Compliance and Quality Assurance in Hold Time Studies

Ensuring that hold time studies comply with regulatory requirements is essential for the pharmaceutical industry’s operations. Regulatory expectations from organizations like the EMA, the FDA, and the MHRA (UK) provide valuable frameworks. Compliance with guidance documents such as Annex 15 ensures that the processes meet standards of quality, safety, and efficacy. Incorporating robust quality assurance measures throughout the hold time studies can:

• Facilitate audits and inspections.
• Guarantee traceability and accountability within validation efforts.
• Enhance reliability and accuracy of data used for decision-making.

The comprehensive alignment with regulatory requirements fosters a culture of quality compliance, creating a sustainable pathway for ongoing operations and product safety in pharmaceutical practices.

Final Thoughts on Hold Time Studies

The relevance of effective hold time studies framed around temperature, conductivity, and pH cannot be overstated. As pharmaceutical stakeholders, the responsibility to ensure products maintain their integrity across hold times lies within rigorous validation processes and adherence to best practices. The steps outlined in this guide serve as a roadmap for professionals looking to establish compliant and reliable hold time processes in their operations. With the right practices in place, pharmaceutical organizations can not only comply with regulatory expectations but also ensure the quality and safety of the products that ultimately reach patients.